<DOC>
	<DOCNO>NCT00297362</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness galantamine hydrobromide patient Alzheimer 's disease receive responded treatment medication similar galantamine hydrobromide .</brief_summary>
	<brief_title>A Study Safety Effectiveness Galantamine Hydrobromide Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Galantamine hydrobromide medication approve treatment symptom Alzheimer 's disease . In accordance international guideline , study conduct drug market continue evaluate expand knowledge regard safety . This multi-center , open-label ( people involve know identity intervention ) , observational study ( individual observe certain outcome measure - attempt make affect outcome ) collect information regard safety effectiveness galantamine hydrobromide patient Alzheimer 's disease . Patients prescribed galantamine hydrobromide initial treatment type medication Alzheimer 's disease fail previous treatment similar medication type Alzheimer 's disease receive galantamine hydrobromide 6 month . The individual physician responsible treatment Alzheimer 's disease administer galantamine hydrobromide dos appropriate patient continue oversee care . No medication supply sponsor study . Safety evaluation ( incidence adverse event , physical exam , vital sign laboratory test ) perform throughout study . Effectiveness determine use standard test rating scale ass mental status , functioning , think , behavior , judgment language ( Neuropsychiatric Inventory , [ NPI ] , Mini Mental Status Exam [ MMSE ] Clinical Global Impression-Caregiver [ CGI-Caregiver ] ) . Assessments conduct monthly first 3 month end 6 month treatment . Galantamine hydrobromide treatment discontinue indication effectiveness . At end study , treat physician may continue treatment galantamine hydrobromide respond patient appropriate . The study hypothesis galantamine hydrobromide effective treating symptom associate Alzheimer 's disease safe well-tolerated . Observational study -No investigational drug administer</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Patients score 1026 Mini Mental Status Exam Patients yet receive treatment Alzheimer 's disease medication similar galantamine patient treat medication similar galantamine hydrobromide discontinue medication due lack effectiveness poor tolerability ( adverse event ) Patients severely decrease liver kidney function Patients digestive system urinary blockage recover digestive system urinary bladder surgery Patients clinically significant unstable uncontrolled hormonal mental disease Patients unable take medication either alone help another person available entire study period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Brain Disease</keyword>
	<keyword>Memory Loss</keyword>
	<keyword>Caregiver</keyword>
	<keyword>Galantamine hydrobromide</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Mental Disorders</keyword>
</DOC>